Condition: Non-Small Cell Lung Cancer (NSCLC) · Sponsor: Promontory Therapeutics Inc.
This is a Phase 1/2, open-label, multi-center, non-randomized, dose-escalation study of PT-112 in combination with the anti-PD-L1 antibody, avelumab, in selected advanced solid tumors. The study is to be conducted in two parts: the Dose Escalation Phase of PT-112 within the combination and the Dose Confirmation Phase in patients with non-small cell lung cancer who will be treated at the RP2D.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Arizona | Phoenix, Arizona, United States | — |
| Colorado | Aurora, Colorado, United States | — |
| Florida | Jacksonville, Florida, United States | — |
| Minnesota | Rochester, Minnesota, United States | — |
| University of Texas MD Anderson Cancer Center | Houston, Texas, United States | — |
| Lausanne | Lausanne, Switzerland | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03409458